“Biosimilars”

4 result(s)
Cost Management
New CMS rule enables Medicare Part B Payors to use step therapy to direct patients to lower-cost, clinically appropriate medications first, giving them an opportunity to implement... More
Briefing
Cost Management
Our formulary strategies effectively leverage competition in the pharmaceutical market to help reduce costs and trend for PBM clients. More
Video
Drug Pipeline
Scientific developments are altering the pace and focus of specialty drug development, while regulatory changes are shortening approval times. This poses new challenges for payors... More
Briefing
DNA double helix
Specialty
The Biologics Price Competition and Innovation (BPCI) Act of 2009 established a “shortened” pathway for two categories of biological products that are demonstrated to be... More
Feature